EB618 (Oral Oxyntomodulin Tablet)
Also known as: Oral OXM tablet, Oral dual GLP-1/glucagon, Entera OXM program
Overview
EB618 is an oral tablet formulation of oxyntomodulin (OXM) being developed by Entera Bio for metabolic and fibrotic conditions, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Oxyntomodulin is a 37-amino-acid gut peptide co-secreted with GLP-1 by intestinal L-cells after a meal. Unlike pure GLP-1 receptor agonists such as semaglutide, oxyntomodulin activates both the GLP-1 receptor (driving satiety and glycemic control) and the glucagon receptor (driving energy expenditure and potentially better preservation of lean mass during weight loss). Dual GLP-1/glucagon agonism has been a major focus of obesity drug development; injectable dual agonists such as cotadutide and survodutide have shown efficacy in trials. EB618 applies Entera's proprietary tablet excipient platform — the same technology underpinning EB613 and EB612 — to the oxyntomodulin scaffold. As of May 2026 the program is in preclinical development. Non-human primate pharmacokinetic data have been submitted to ENDO 2026.
Mechanism of Action
Oxyntomodulin binds and activates two class B G-protein-coupled receptors: GLP-1R and glucagon receptor (GCGR). GLP-1R activation slows gastric emptying, suppresses appetite via hypothalamic pathways, and enhances glucose-dependent insulin secretion. GCGR activation increases hepatic glucose output and energy expenditure, and may improve hepatic lipid handling — a property of particular interest in MASH. The dual mechanism produces weight loss with a different body-composition signature than pure GLP-1 agonism: theoretically less lean mass loss and better metabolic efficiency. Tuning the GLP-1R/GCGR activation ratio is the core pharmacological design challenge for any OXM-class drug.
Potential Benefits
- Dual GLP-1/glucagon receptor activation versus single-receptor GLP-1 agonism
- Potential for better lean mass preservation during weight loss
- Mechanistic rationale for MASH and fibrotic liver disease beyond pure GLP-1 agents
- Oral tablet route in a class currently dominated by injectables
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Investigational only — not available outside trial |
| Intermediate | Investigational only — not available outside trial |
| Advanced | Investigational only — not available outside trial |
| Cycle Duration | Not yet defined |
EB618 is not commercially available. Patients seeking GLP-1 or dual-agonist metabolic therapy should consult their physician about approved options (semaglutide, tirzepatide, etc.).
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (tablet) Not publicly disclosed
Oxyntomodulin tablet built on the Entera tablet excipient platform.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Reconstitution
| Storage | Per trial protocol |
|---|
No reconstitution required.
Need exact syringe measurements?
Amino Acid Sequence
Native human oxyntomodulin is 37 AA: His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala. Specific EB618 analog sequence not publicly disclosed.
Side Effects & Safety
- Preclinical only — human safety profile not characterized
- GLP-1 class effects expected: nausea, vomiting, delayed gastric emptying
- Glucagon agonism may increase hepatic glucose output and could raise fasting glucose in some patients — the design challenge is balancing the two arms
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Investigational only
FDA Safety Information
Investigational. No human safety data publicly available as of May 2026.
Pharmacokinetics
| Half-Life | Native oxyntomodulin half-life is approximately 12 minutes due to rapid DPP-4 cleavage; long-acting OXM analogs are engineered for resistance to DPP-4 and extended half-life. EB618 PK parameters not publicly disclosed. |
|---|---|
| Storage | Per clinical trial protocol |
Synergistic Compounds
The following compounds have been studied alongside EB618 (Oral Oxyntomodulin Tablet) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
Wisconsin Group Shows Class B1 GPCR Peptides Can Drop the Helix — and Pick Their Pathway
Wisconsin chemists put D-amino acids into glucagon and PTH(1-34), broke the alpha-helix that textbooks demand, and still got biased class B1 GPCR agonists.
Inside the Peptide Gray Market: Influencers, Telehealth, and the FDA Advisory Panel Kennedy Just Reshuffled
AP and WSJ this week describe a real policy reversal in motion: Kennedy is firing FDA compounding advisers as BPC-157, TB-500, CJC-1295 sales surge online.
Ascletis ASC35 Clears FDA For Phase 1: A Once-Monthly GLP-1/GIP Peptide With A Lipid Depot
Ascletis ASC35, a once-monthly GLP-1/GIP peptide using a self-assembling lipid depot, cleared FDA IND for Phase 1 head-to-head vs weekly tirzepatide June 23.
FDA flags unapproved GLP-1 compounding risks: telehealth claims, cold-chain failures, dosing errors
FDA highlights unapproved GLP-1 risks—fraudulent labels, warm shipments, and dosing errors—while warning telehealth companies against misleading ‘generic’ claims.